La cadena de opciones muestra datos clave de las opciones de acciones de PMGC Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para PMGC Holdings..

PMGC Holdings (NASDAQ:ELAB) Bolsa, Cadena de Opciones

Elevai Labs

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

PMGC Holdings Inc

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

BCYC

Needham Reiterates Buy on Bicycle Therapeutics, Maintains $30 Price Target

WIIM

MULN

Mullen Automotive shares are trading lower after the company announced a 1-for-100 reverse stock split.

IMS is One of the Largest Independent Multi-Specialty Practices in the State
Arizona Represents 15th State in National Primary Care-Centric Care Delivery Network
ARLINGTON, Va., April 09, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) announced it has signed a definitive agreement to enter Arizona in partnership with Integrated Medical Services, Inc. (IMS), one of the largest independent multi-specialty practices in the state, with approximately 70 physicians and advanced practice providers caring for patients in 21 locations. The group manages over 28,000 attributed lives in a variety of value-based care arrangements across Commercial, Medicare, Medicare Advantage and Medicaid.
With this transaction, Privia Health launches Privia Medical Group—Arizona, providing a compelling new alternative for independent providers across the state to care for all patients regardless of the reimbursement model. IMS will serve as the anchor practice with a long-term management agreement with Privia Health and continue to be physician-owned and operated.
IMS is expected to be implemented on the Privia Platform in the fourth quarter of 2025. The transaction and launch in Arizona is expected to be profitable starting in the fourth quarter of 2025 and for full-year 2026. Financial terms and additional details were not disclosed.
"We are extremely pleased to partner with IMS, one of the largest independent practices in Arizona, as we expand Privia's national presence," said Jason Ross, EVP, Medical Groups, Privia Health. "The demographics of the Arizona market offer a compelling value-based care opportunity. We look forward to building on the IMS providers' culture of delivering high quality care in the community as we continue to execute our strategy of aligning with like-minded providers and practices to offer high quality care to patients across the U.S."

Contracts

PRVA

Privia Health Group Signs Definitive Agreement To Enter Arizona In Partnership With Integrated Medical Services. Group Manages Over 28,000 Attributed Lives

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Hold to Hold.

ZIMV

Needham Reiterates Hold on ZimVieto Hold

Wells Fargo analyst Elyse Greenspan upgrades Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Underweight to Equal-Weight and raises the price target from $225 to $247.

Upgrades

Wells Fargo Upgrades Travelers Companies to Equal-Weight, Raises Price Target to $247

GEVO

Gevo Signs SAF Scope 1 And Scope 3 Voluntary Carbon Credit Offtake Agreement With Future Energy Global

Needham analyst Mike Matson reiterates Enovis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENOV#NYSE">ENOV</a>) with a Buy and maintains $64 price target.

ENOV

Needham Reiterates Buy on Enovis, Maintains $64 Price Target

DUBLIN, Ireland, April 09, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) ("Fusion Fuel" or the "Company"), a leading provider of full-service energy engineering and advisory solutions, today announced that it has signed a non-binding letter of intent ("LOI") to acquire 100% of a privately held British fuel distribution company (the "Target").
In the proposed acquisition, the Company will purchase 100% of the outstanding shares of the Target from its shareholders for total consideration valued at £50 million, consisting of £25 million in cash funded through debt financing, £2 million in cash financed from a capital raise, £8 million in the Company's shares subject to a make-whole agreement, and two additional payments of £7.5 million cash each within nine months and 18 months from the closing.
The Target reported over $50 million in revenue and $4 million in net income for the year ending in 2023 and delivered strong growth in 2024, generating over $54 million in revenue and $7 million in net income. The transaction, if consummated, would mark a significant expansion of Fusion Fuel's presence in the energy distribution sector, aligning with the Company's broader strategic objectives.
John-Paul Backwell, Chief Executive Officer of Fusion Fuel, commented: "This proposed transaction reflects our progress in executing our growth strategy, which began with our acquisition of Quality Industrial Corp. late last year. Our short-term priority is to build a synergistic portfolio of profitable and cash-generating businesses across the energy value chain. In addition to significantly increased revenues and profitability, acquiring this United Kingdom-based fuel distribution company would enable us to expand our footprint in the energy distribution space while also broadening our geographic presence into a key new market."
The LOI is non-binding, and consummation of the transaction remains subject to further due diligence, the negotiation of definitive agreements, and the satisfaction of customary closing conditions, including regulatory approvals. The Company expects to provide further updates as discussions progress.

HTOO

Fusion Fuel Signs Non-Binding Letter Of Intent To Acquire 100% Of Privately Held British Fuel Distribution Company

As of April 9, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Inno Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>)</h3>
<ul>
<li>On Dec. 13, 2024, Inno Holdings announced expansion into electronic product trading and digital transformation initiatives. Mr. Ding Wei, Chief Executive Officer of INNO said, &#8220;INNO plans to expand its trading business into the electronic products industry, including cell phones, computers, tablets, and more. We have a professional team dedicated to helping our business partners achieve greater value. In the future, we intend to collaborate with more partners to explore new business opportunities and create additional value for both our partners and shareholders.&#8221; The company's stock gained around 23% over the past five days and has a <a href="https://www.benzinga.com/quote/INHD">52-week high of $9.10</a>.</li>
<li>RSI Value: 73.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>INHD Price Action: Shares of Inno Holdings gained 4.6% to close at $5.70 on Tuesday.</li>
<li>Edge Stock Ratings: 71.55 Momentum score with Value at 43.76. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/inhd"><img loading="lazy" decoding="async" width="482" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09035953/image-46.png" alt="" class="wp-image-863219" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09035953/image-46.png 482w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/09035953/image-46-300x110.png 300w" sizes="(max-width: 482px) 100vw, 482px" /></a></figure>
<h3 class="wp-block-heading">Radius Recycling Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>)</h3>
<ul>
<li>On April 4, the Company reported a loss per share from continuing operations of $1.15 in the second quarter, versus a year-ago loss of $1.19 per share. The company's stock gained around 125% over the past month and <a href="https://www.benzinga.com/quote/RDUS">has a 52-week hig</a>h of $29.20.</li>
<li>RSI Value: 75.9</li>
<li>RDUS Price Action: Shares of Radius Recycling fell 0.6% to close at $28.53 on Tuesday. </li>
</ul>
Unlock the rest of the BZ Edge Rankings and see <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how top stocks stack up</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44684755/top-3-industrials-stocks-you-may-want-to-dump-this-month">Top 3 Industrials Stocks You May Want To Dump This Month</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

INHD

RDUS

Top 2 Materials Stocks That May Fall Off A Cliff This Quarter

8 analysts have shared their evaluations of Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $164.38, a high estimate of $184.00, and a low estimate of $141.00. This current average represents a 5.06% decrease from the previous average price target of $173.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1744203661_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Extra Space Storage by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $149.00&#x7C;$165.00 &#x7C; 
&#x7C;Ravi Vaidya &#x7C;Mizuho &#x7C;Announces &#x7C;Outperform &#x7C; $141.00&#x7C;- &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $181.00&#x7C;$184.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Perform &#x7C; $165.00&#x7C;$167.00 &#x7C; 
&#x7C;Brad Heffern &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $163.00&#x7C;$167.00 &#x7C; 
&#x7C;Eric Luebchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $165.00&#x7C;$170.00 &#x7C; 
&#x7C;Brendan Lynch &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $184.00&#x7C;$192.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Maintains &#x7C;Sector Perform &#x7C; $167.00&#x7C;$167.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Extra Space Storage. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Extra Space Storage compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Extra Space Storage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Extra Space Storage's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Extra Space Storage analyst ratings.</a>
<h2>Delving into Extra Space Storage's Background</h2>
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 4,000 self-storage properties in 42 states, with over 300 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
<h3>Extra Space Storage: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Extra Space Storage's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.02% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Extra Space Storage's net margin excels beyond industry benchmarks, reaching 31.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Extra Space Storage's ROE stands out, surpassing industry averages. With an impressive ROE of 1.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Extra Space Storage's ROA stands out, surpassing industry averages. With an impressive ROA of 0.92%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Extra Space Storage's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.93.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Extra Space Storage Stock

Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $477.08, along with a high estimate of $512.00 and a low estimate of $405.40. Marking an increase of 2.4%, the current average surpasses the previous average price target of $465.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1744203653_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Elevance Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $505.00&#x7C;$455.00 &#x7C; 
&#x7C;David Toung &#x7C;Argus Research &#x7C;Maintains &#x7C;Hold &#x7C; $405.40&#x7C;$405.40 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $478.00&#x7C;$483.00 &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $485.00&#x7C;$485.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $512.00&#x7C;$501.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Elevance Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Elevance Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Elevance Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ELV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Elevance Health analyst ratings.</a>
<h2>Discovering Elevance Health: A Closer Look</h2>
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
<h3>A Deep Dive into Elevance Health's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3M period, Elevance Health showcased positive performance, achieving a revenue growth rate of 6.55% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.92%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Elevance Health's ROE excels beyond industry benchmarks, reaching 0.98%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Elevance Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.36% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.76, Elevance Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

5 Analysts Assess Elevance Health: What You Need To Know

Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $17.62, along with a high estimate of $20.00 and a low estimate of $14.00. This current average represents a 12.43% decrease from the previous average price target of $20.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1744203644_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Host Hotels &amp; Resorts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Katz &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $14.00&#x7C;$20.00 &#x7C; 
&#x7C;Patrick Scholes &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $17.00&#x7C;$20.00 &#x7C; 
&#x7C;Stephen Grambling &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $15.00&#x7C;$16.00 &#x7C; 
&#x7C;Nick Joseph &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $19.00&#x7C;$21.00 &#x7C; 
&#x7C;Floris Van Dijkum &#x7C;Compass Point &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;William Crow &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $20.00&#x7C;$23.00 &#x7C; 
&#x7C;Dori Kesten &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;Robin Farley &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$19.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Host Hotels &amp; Resorts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Host Hotels &amp; Resorts compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Host Hotels &amp; Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Host Hotels &amp; Resorts's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Host Hotels &amp; Resorts analyst ratings.</a>
<h2>Unveiling the Story Behind Host Hotels &amp; Resorts</h2>
Host Hotels &amp; Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
<h3>Host Hotels &amp; Resorts: A Financial Overview</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Host Hotels &amp; Resorts showcased positive performance, achieving a revenue growth rate of 7.94% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Host Hotels &amp; Resorts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.62%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Host Hotels &amp; Resorts's ROA excels beyond industry benchmarks, reaching 0.83%. This signifies efficient management of assets and strong financial health.
Debt Management: Host Hotels &amp; Resorts's debt-to-equity ratio is below the industry average at 0.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About Host Hotels & Resorts

Stock Split

Mullen Automotive Inc. Announces 1-for-100  Reverse Stock Split Effective April 11, 2025

UBS analyst Arpine Kocharyan initiates coverage on United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Neutral rating and announces Price Target of $49.

Initiation

PRKS

UBS Initiates Coverage On United Parks & Resorts with Neutral Rating, Announces Price Target of $49

Throughout the last three months, 14 analysts have evaluated Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.5, a high estimate of $50.00, and a low estimate of $29.00. This upward trend is apparent, with the current average reflecting a 3.46% increase from the previous average price target of $41.08.
<img src="https://www.benzinga.com/files/images/story/2025/1744203631_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Toast by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Adam Frisch &#x7C;Evercore ISI Group &#x7C;Announces &#x7C;In-Line &#x7C; $29.00&#x7C;- &#x7C; 
&#x7C;Will Nance &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $38.00&#x7C;$43.00 &#x7C; 
&#x7C;Daniel Perlin &#x7C;RBC Capital &#x7C;Raises &#x7C;Sector Perform &#x7C; $45.00&#x7C;$40.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $48.00&#x7C;$43.00 &#x7C; 
&#x7C;Tien-Tsin Huang &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $42.00&#x7C;$36.00 &#x7C; 
&#x7C;Timothy Chiodo &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $47.00&#x7C;$41.00 &#x7C; 
&#x7C;Rufus Hone &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $48.00&#x7C;$46.00 &#x7C; 
&#x7C;David Koning &#x7C;Baird &#x7C;Raises &#x7C;Neutral &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Josh Baer &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $50.00&#x7C;$46.00 &#x7C; 
&#x7C;Sanjay Sakhrani &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $42.00&#x7C;$40.00 &#x7C; 
&#x7C;Mayank Tandon &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $50.00&#x7C;$50.00 &#x7C; 
&#x7C;Rayna Kumar &#x7C;Oppenheimer &#x7C;Announces &#x7C;Outperform &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Jeff Cantwell &#x7C;Wells Fargo &#x7C;Raises &#x7C;Underweight &#x7C; $30.00&#x7C;$25.00 &#x7C; 
&#x7C;Will Nance &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $40.00&#x7C;$45.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Toast. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Toast compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Toast's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Toast's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TOST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Toast analyst ratings.</a>
<h2>Get to Know Toast Better</h2>
Toast is a US-based restaurant technology company that provides point-of-sale, payment processing, and various software services to 134,000 restaurant locations across the United States as of December 2024. The firm generates sales from software subscription fees, as a percentage take rate from each financial transaction it processes, from loan origination and servicing fees from its Toast Capital arm, and from hardware installation and professional services. Unlike competitors, Toast intermediates every payment transaction on its platform; it processed some $159 billion in gross platform volume in 2024. The firm's product offerings span point-of-sale systems, inventory and payroll management, delivery integration, e-commerce ordering, reservation management, and loyalty programs.
<h3>Toast's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Toast's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.15%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Toast's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 2.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Toast's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.16%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Toast's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Toast's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TOST

Assessing Toast: Insights From 14 Financial Analysts

Fidelity National Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) short percent of float has fallen 9.68% since its last report. The company recently reported that it has 2.47 million shares sold short, which is 1.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Fidelity National Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744203629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Fidelity National Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Fidelity National Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Fidelity National Finl's peer group average for short interest as a percentage of float is 2.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

What's Driving the Market Sentiment Around Fidelity National Finl?

Monolithic Power Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NYSE">MPWR</a>) short percent of float has fallen 11.58% since its last report. The company recently reported that it has 2.30 million shares sold short, which is 6.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monolithic Power Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744203624_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monolithic Power Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monolithic Power Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monolithic Power Systems's peer group average for short interest as a percentage of float is 5.17%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MPWR

Is the Market Bullish or Bearish on Monolithic Power Systems?

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Evolus, presenting an average target of $24.25, a high estimate of $27.00, and a low estimate of $22.00. This current average has increased by 2.67% from the previous average price target of $23.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1744203621_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $25.00&#x7C;$22.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $22.00&#x7C;$20.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $22.00&#x7C;$22.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Evolus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolus compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Evolus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EOLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Evolus Better</h2>
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
<h3>Evolus's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Evolus showcased positive performance, achieving a revenue growth rate of 29.42% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Evolus's net margin excels beyond industry benchmarks, reaching -8.6%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -119.02%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Evolus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Evolus's debt-to-equity ratio surpasses industry norms, standing at 23.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EOLS

Breaking Down Evolus: 8 Analysts Share Their Views

Ross Stores's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NYSE">ROST</a>) short percent of float has fallen 8.93% since its last report. The company recently reported that it has 4.94 million shares sold short, which is 1.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ross Stores Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744203618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ross Stores has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ross Stores's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ross Stores's peer group average for short interest as a percentage of float is 13.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ROST

How Do Investors Really Feel About Ross Stores?

8 analysts have expressed a variety of opinions on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Humana, presenting an average target of $280.38, a high estimate of $316.00, and a low estimate of $255.00. This upward trend is evident, with the current average reflecting a 1.31% increase from the previous average price target of $276.75.
<img src="https://www.benzinga.com/files/images/story/2025/1744203611_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $316.00&#x7C;$305.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $256.00&#x7C;$257.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $270.00&#x7C;$255.00 &#x7C; 
&#x7C;Ben Hendrix &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $283.00&#x7C;$283.00 &#x7C; 
&#x7C;Sarah James &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Neutral &#x7C; $290.00&#x7C;$290.00 &#x7C; 
&#x7C;Erin Wright &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $285.00&#x7C;$301.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $255.00&#x7C;$253.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $288.00&#x7C;$270.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Humana. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Humana's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Humana's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Key Indicators: Humana's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Humana showcased positive performance, achieving a revenue growth rate of 10.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Humana's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.37%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Humana's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.08%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Humana's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.44%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Humana

Health Care

Press Releases

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

PMGC Holdings Announces Share Repurchases from Existing Shareholders

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

AXIL Brands

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

PMGC Holdings

Flora Growth

Mannatech

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives Intl

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

Shineco

Synergy CHC

United-Guardian

Upexi

Eon Labs

Screenshot 2024-05-25 at 12.27.19 AM

Biotech

Interview

General

Ozempic And Wegovy Can Lead To Major Muscle Loss – This Company May Have A Solution

Screenshot 2024-05-16 at 5.52.00 PM

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

PMGC Holdings

PMGC Holdings (ELAB) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL